15

L&K Biomed Ltd.

156100 · KQ · Healthcare / Medical Devices

4,775.00KRW-205.00 (-4.12%)

Price History

Full chart

Market Stats

Previous Close4,980.00
Open5,000.00
Day Range4,705.00 – 5,050.00
52-Week Range2,730.00 – 16,400.00
Volume252.22K
Market Cap139.92B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.76
50-Day Avg4,545.70
200-Day Avg8,034.30

About

L&K Biomed Ltd., a medical company, manufactures and sells spinal implants in South Korea, the United States, Thailand, and internationally. The company offers spinal products comprising BlueEX-T, BluEX-TC, BluEX-A, BlueEX-L, and BluEX-ATP; BluEX-LT, an advanced lateral cage system for spinal lordosis restoration; PathLoc-TM, an expandable TLIF/PLIF lumbar cage system; AccelFix-XL, an expandable lateral lumbar cage system; AccelFix-XTP, an expandable lumbar cage system for anterior-to-psoas approach; and PathLoc-TA, an expandable ALIF anterior lumbar cage system. It also provides CastleLoc-C, an anterior cervical interbody fusion cage; CastleLoc-P, an anterior cervical plate system; CastleLoc-S, a posterior cervical fixation system; AccelFix-S, a lumbar spinal fixation screw system; AccelFix-LP, a lumbar plate system; OpenLoc-L, a lumbar spinal fixation system; LnK Lumbar Peek Cages for posterior lumbar interbody fusion procedures; PathLoc-L, a MIS spinal system; AccelFix-MIS, a spinal fixation system; and PathLoc-SI sacroiliac fixation and fusion system that offers fusion and stabilization of the SI joint. In addition, the company offers CastleLoc Pectus bar system for the correction of pectus excavatum. L&K Biomed Ltd. was founded in 2008 and is headquartered in Yongin-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Guk-jin Kang
  • Employees105
  • Headquarters16-25, Dongbaekjungang-ro 16beon-gil, Yongin-si, South Korea, 17015, Korea
  • Websitehttps://www.lnkbiomed.com

Leadership

  • Mr. Guk-jin KangCEO & Director · b. 1966
  • Mr. Kang Kuk NamExecutive Director · b. 1975

Financials

Income Statement

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Revenue19.77B29.90B36.09B38.92B
Growth (%)-+51.28%+20.69%+7.84%
Cost of Revenue4.88B4.14B5.84B6.77B
Gross Profit14.89B25.77B30.25B32.16B
Gross Margin75.32%86.16%83.81%82.62%
Operating Expense28.92B32.25B27.17B31.44B
Operating Income-14.03B-6.49B3.08B715.12M
Operating Margin-70.98%-21.70%8.53%1.84%
EBITDA-11.79B-2.15B15.07B-11.29B
EBITDA Margin-59.64%-7.20%41.75%-29.01%
Net Income-13.63B-1.87B9.74B-16.30B
Net Income Margin-68.93%-6.24%27.00%-41.87%
R&D1.37B1.33B2.05B2.46B
R&D as % of Total Revenue6.92%4.45%5.69%6.32%
Interest Expense2.21B2.00B2.68B3.07B
Interest Expense % of Total Revenue11.16%6.69%7.43%7.90%

Balance Sheet

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Assets52.66B62.76B83.06B83.48B
Total Liabilities41.90B32.18B47.03B44.85B
Total Equity12.27B35.35B42.50B45.48B
Cash7.39B5.05B3.83B3.18B
Net Debt15.81B6.79B18.52B13.70B

Cash Flow

Currency: KRW2019-12-312020-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow---6.88B-1.37B-7.43B-13.88B
Capital Expenditure0002.10B615.13M3.13B
Free Cash Flow---6.88B-3.47B-8.05B-17.01B
FCF to OCF--100.00%253.21%108.28%122.56%

Earnings

Report DateMar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-------------------------------------
EPS Actual-163.92-80.11100.43-896.30-94.64497.1497.02-123.57-512.69-137.75-247.80-22.84-14.0116.37-873.93104.02-318.67-218.76-279.45-203.98-371.36-11.61-328.77128.767.7569.42-247.12178.5749.81-56.51375.89-30.37-128.29132.59-828.86374.04338.78
Surprise-------------------------------------
Timing-------------------------------------

Key Statistics & Ratios

Market Cap139.92B
Enterprise Value140.06B
Trailing P/E0.00
Forward P/E0.00
Price / Sales3.50
Price / Book2.07
Revenue (TTM)39.94B
Gross Profit (TTM)33.18B
EBITDA3.20B
Profit Margin6.93%
Operating Margin10.86%
Return on Equity4.54%
Return on Assets0.22%
Shares Outstanding22.35M
Shares Float19.67M
Beta0.76
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Oct 6, 20141.5:1